by SignalFactory · January 17, 2020 | 08:29:59 UTC
At the JP Morgan Healthcare Conference, Teva CEO Kare
Schultz said the company was on target with streamlining and debt reduction and
outlined its strategy for the Chinese market.
In his presentation, Schultz gave a detailed account of
the streamlining program that Eva began in 2017, mentioning among other things
that thirteen production sites had been shut down or sold and that ten more
were in the process of shut-down or sale, and that the goal of annual cost
savings of $3 billion had been achieved.
Schultz pointed out that Teva had grown through more than
twenty acquisitions in twenty years, resulting in too many offices and too many
R&D locations, many of which had now been closed. “We will continue
optimizing the manufacturing footprint. Again, in connection with the full-year
earnings in February, we will give you a more precise picture of what the plans
will be for the coming years in order to optimize the gross margin and the
On Teva’s debt, Schultz reminded his listeners that it
had ballooned because of the acquisition of Actavis in 2016 for nearly $40
billion and that over the past two years the company had recycled debt, and had
reduced its debt over the period through assets sales and through its cash
flow, the goal is to continue to reduce it. At the end of the third quarter of
2019, the debt totaled $26.9 billion.
Schultz highlighted Teva’s entry into biosimilars, with
the launch in November of Truxima, equivalent of Rituximab for treatment of
blood cancers and inflammatory conditions, which he said was successful.
“There is a strong future the way I see it for both traditional generics
and biosimilars in the US and the pricing has now stabilized,” he said,
adding that in Europe “the situation has been calmer.” He said that
there was now low single-digit growth in European generics “so we have a
very stable, solid business and we are still churning out you know hundreds of
launches every a year.”
A new market for Teva will be China, where the company
has never been a significant player. “I’m not a strong believer in joint
ventures in this kind of markets,” Schultz said, “So we’ve decided to
do it organically and we’ve had the luck that the Chinese government had
realized that certain products have never been launched in China. So the
government has made a list, it’s publicly available, of pharmaceuticals that
they would like to have in the Chinese market, where nobody ever wanted to
spend the money doing the Phase III trials in the whole very, very long
regulatory process in China.
“It turns out that because we do so many products,
we do some of these products as well. So we’ve just launched Treanda in China.
We have Austedo that has been filed. And the benefit here is we can do that
without doing any trials in China because the Chinese authorities have realized
they would like to have these products in the marketplace for the benefit of
“So that means that we’re slowly building up. These
are not big numbers today but these are 100% controlled numbers from our side.
We don’t have a partner that’s controlling things. And we will be growing very
big in terms of percentages but from a small base, but it will be profitable
the whole way. And in five, ten years China hopefully will be a significant
part of our business.”
Schultz summed up by saying, “So what I think I have
proven to you is that we’ve done the restructuring. We’ve done exactly what we
promised to do. We promised to reduce the spend base with $3 billion,
everything included was $16.3 billion in ’17. It has to be less than $13.3
billion in ’19. And I can promise you that’s the case. We’ve also handled the
debt nicely, taking it down more than $8 billion over two years and we’ll
continue to do so. And that means, of course, our ratios on the debit side will
continue to improve over the coming years. And we also now have a situation
where the drag versus the growth is looking positive. So we’re expecting to see
low revenue growth in 2020. And then, of course, higher once we get into the
future simply because of the fact that the drag from Copaxone disappears more
or less, while we still see Austedo and Ajovy growing and while we see the
combination of US generics and biosimilars also having a very stable to the
All information on this website is of a general nature. The information is not adapted to conditions that are specific to your person or entity. The information provided can not be considered as personal, professional or legal advice or investment advice to the user.
Signal Factory is not represented as a registered investment consultant or brokerage dealer nor offers to buy or sell any of the financial instruments mentioned in the service offered.
While Signal Factory believes that the content provided is accurate, there are no explicit or implied warranties of accuracy. The information provided is believed to be reliable; Signal Factory does not guarantee the accuracy or completeness of the information provided. Third parties refer to Signal Factory to provide technology and information if a third party fails, and then there is a risk that the information may be delayed or not delivered at all.
All information and comments contained on this website, including but not limited to, opinions, analyzes, news, prices, research, and general, do not constitute investment advice or an invitation to buy or sell any type of instrument. Signal Factory assumes no responsibility for any loss or damage that may result, directly or indirectly, from the use or dependence on such information.
All information contained on this web site is a personal opinion or belief of the author. None of these data is a recommendation or financial advice in any sense, also within the meaning of any commercial act or law. Writers, publishers and affiliates of Signal Factory are not responsible for your trading in any way.
The information and opinions contained in the site are provided for information only and for educational reasons, should never be considered as direct or indirect advice to open a trading account and / or invest money in Forex trading with any Forex company . Signal Factory assumes no responsibility for any decisions taken by the user to create a merchant account with any of the brokers listed on this website. Anyone who decides to set up a merchant account or use the services, free of charge or paid, to any of the Forex companies mentioned on this website, bears full responsibility for their actions.
Any institution that offers a service and is listed on this website, including forex brokers, financial companies and other institutions, is present only for informational purposes. All ratings, ratings, banners, reviews, or other information found for any of the above-mentioned institutions are provided in a strictly objective manner and according to the best possible reflection of the materials on the official website of the company.
Forex trading is potentially high risk and may not be suitable for all investors. The high level of leverage can work both for and against merchants. Before each Forex investment, you should carefully consider your goals, past experience and risk level. The opinions and data contained on this site should not be considered as suggestions or advice for the sale or purchase of currency or other instruments. Past results do not show or guarantee future results.
Neither Signal Factory nor its affiliates ensure the accuracy of the content provided on this Site. You explicitly agree that viewing, visiting or using this website is at your own risk.